Stevenage, UK, 8 January 2026 – NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-08 08:00:382026-07-31 12:02:19NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s
Stevenage, UK, 1 December 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO). In his role at NRG, Paul will be project lead for NRG5051 which […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-12-01 08:00:502026-07-31 12:02:23NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer
Stevenage, UK, 23 October 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-10-23 08:00:452026-09-10 13:57:33NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies
Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-09-08 08:00:232026-07-31 12:02:30NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s
Stevenage, UK, 8 January 2026 – NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a […]
NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer
Stevenage, UK, 1 December 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO). In his role at NRG, Paul will be project lead for NRG5051 which […]
NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies
Stevenage, UK, 23 October 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; […]
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, […]